The UK medical cannabis market generated over 300 million euros in 2025. Patient numbers are rising and the supply chain remains structurally dependent on overseas flower. Canada is the single largest source country for UK medical cannabis imports by volume. That position opens a real commercial window for Canadian LPs. The catch is a dual-regulator framework: both Health Canada and UK-side compliance must be satisfied before a single gram moves.
This guide covers what a Canadian LP needs in 2026 to establish or expand UK supply relationships. It walks through which regulators govern each side of the shipment, what licences are required, how the documentation chain is built, and where the process most commonly fails.
The UK regulatory framework: two regulators, one shipment
UK medical cannabis importation is governed by two separate bodies. Both must be satisfied in parallel.
The Home Office and controlled drug import licences
Cannabis is classified as a Class B, Schedule 1 controlled drug under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001. Companies importing, exporting, or supplying CBPMs in the UK must hold a controlled drug import licence from the Home Office's Drugs and Firearms Licensing Unit (DFLU). A narrow statutory exemption exists but rarely applies to commercial supply arrangements.
Import licences are issued per shipment and are valid for three months. Per-shipment licensing is one of the main structural friction points in the UK supply chain. It creates gaps between consignments when processing times extend. The Home Office current SLA for controlled drug licence applications is 8 to 10 weeks from receipt of complete information.
The MHRA and GMP certification
The Medicines and Healthcare products Regulatory Agency (MHRA) is the medicines regulator and the second gatekeeper. For unlicensed CBPMs imported as "specials" (products imported for an individual patient on a specialist prescription), the MHRA requires:
- A valid GMP certificate for the Canadian site of manufacture
- A 28-day advance notification to the MHRA before the intended import date (with an expedited route available for urgent clinical need)
- A documented audit trail confirming clinical need, traceable through the entire supply chain
Brexit ended automatic recognition of EMA manufacturing authorisations. A Canadian LP exporting to Germany under EU-GMP documentation must go through a separate MHRA authorisation process to supply the UK. The two frameworks have run independently since 2021.
The Canadian side: Health Canada export permit requirements
From the Canadian end, export is governed by the Cannabis Act and its Regulations, which implement Canada's obligations under the Single Convention on Narcotic Drugs, 1961.
Export permit from Health Canada
Health Canada issues export permits only for medical or scientific purposes. Each shipment requires its own permit. See our guide to the Health Canada cannabis export permit process for a full application walkthrough. Each CTLS submission must include:
- Proof that the destination country has issued (or is in the process of issuing) an import permit
- Details of the customs office, sufferance warehouse, or bonded warehouse receiving the shipment
- Documentation confirming the export is solely for medical or scientific purposes
Processing times for Canadian export permits have historically run four to eight weeks, creating a timing challenge that must be coordinated with the UK importer's Home Office licence validity window.
Licence class and permitted activities
Only licence holders under the Cannabis Regulations may export cannabis. The export must align with the activities explicitly authorised under the LP's licence class. LPs whose licence does not cover export activities will need to apply for an amendment before proceeding.
What UK importers look for in a Canadian supplier
A UK Specialist Importer holds both an MHRA WDA(H) and a Home Office controlled drug licence. Before entering a commercial relationship, they evaluate Canadian supply partners on documentation and quality criteria.
Required documentation
| Document | Issuing Body | Purpose |
|---|---|---|
| Health Canada export permit | Health Canada (CTLS) | Per-shipment authorisation to export |
| Home Office import licence | Home Office DFLU | Per-shipment authorisation to import into UK |
| GMP certificate | Health Canada / MHRA | Confirms manufacturing site meets pharmaceutical GMP |
| Certificate of Analysis (COA) | ISO/IEC 17025-accredited lab | Potency, microbials, pesticides, heavy metals per batch |
| Phytosanitary certificate | CFIA | Required for plant-material shipments at UK customs |
| MHRA 28-day notification | MHRA (submitted by importer) | Advance notice of intended import |
Quality standard alignment
The UK does not have a standalone cannabis GMP framework equivalent to EU-GMP or Health Canada GMP. In practice, MHRA expects the manufacturing site to meet standards consistent with EU GMP principles, particularly Annex 7 for herbal medicinal products. Canadian LPs whose quality systems are already EU-GMP-aligned carry a meaningful commercial advantage: MHRA can map those standards to UK expectations without a standalone re-audit. For a detailed comparison, see EU-GMP vs Health Canada GMP for Cannabis Export.
COA panels must cover cannabinoid potency, residual solvents (where applicable), microbial contamination, mycotoxins, pesticide residues, and heavy metals. For a full breakdown of what UK importers expect to see on a COA panel, see our Cannabis Certificate of Analysis guide for B2B buyers. MHRA actively monitors imports and may refuse or delay consignments where product standards or documentation are deficient.
The 5-stage Canada-to-UK supply path
The following sequence applies to a Canadian LP entering the UK market as a flower supplier to a CBPM Specialist Importer.
Stage 1: Identify a qualified UK Specialist Importer. The importer must already hold, or be in the process of obtaining, the Home Office import licence and MHRA WDA(H). Negotiating supply ahead of a credentialled UK partner is premature. The partner's regulatory status is the entry point.
Stage 2: Align on quality documentation. Share batch COAs, the GMP certificate, site audit history, and stability or shelf-life data. Many UK importers conduct a paper-based supplier qualification audit before submitting the Home Office import licence application. The MHRA's GMP certificate requirement for the Canadian site must be confirmed at this stage.
Stage 3: Coordinate permit timelines. The UK importer submits the Home Office import licence application (8 to 10 weeks SLA) and files the MHRA 28-day notification. The Canadian LP applies for a Health Canada export permit through CTLS (four to eight weeks). Both must be active and valid for the same shipment window. Parallel submission is a structural necessity, not an option.
Stage 4: Pre-shipment customs preparation. The CFIA phytosanitary certificate is obtained by the Canadian exporter. The COA for the specific batch being shipped is finalised and attached to shipping documentation. The UK importer coordinates bonded warehouse or sufferance warehouse receipt.
Stage 5: UK customs clearance and quarantine. HM Revenue and Customs (HMRC) and UK Border Force conduct checks on arrival. The product is placed in quarantine at the importer's warehouse pending routine MHRA review. The importer notifies MHRA of arrival per regulatory requirements.
Frequently Asked Questions
Does Canada export cannabis to the UK?
Yes. Canada is the largest source country for UK medical cannabis imports by volume. Canadian LPs may export flower to the UK under a Health Canada export permit for medical purposes. A UK-licensed Specialist Importer with a valid Home Office controlled drug import licence must be in place to receive the shipment.
What licences are required to import cannabis into the UK?
A UK importer needs two licences. First, a Wholesale Distribution Authorisation (WDA(H)) from the MHRA covering controlled drug products. Second, a per-shipment Home Office controlled drug import licence from the DFLU. The import licence is valid for three months. Importers must also notify the MHRA at least 28 days before the intended import date.
Does a Canadian LP need EU-GMP certification to export to the UK?
Not formally. The UK has operated independently of the EMA since Brexit. However, the MHRA expects manufacturing sites to meet standards consistent with EU GMP principles, particularly Annex 7 for herbal medicinal products. LPs whose quality systems are already EU-GMP-aligned are well-positioned for MHRA review. A separate MHRA GMP certificate review is required regardless of existing EU-GMP documentation.
How long does it take to get a Health Canada cannabis export permit?
Processing through the CTLS portal typically runs four to eight weeks. Each shipment requires its own permit. Canadian LPs should apply in parallel with the UK importer's Home Office application to avoid permit timing mismatches within the three-month import licence validity window.
What quality documents does a UK importer require from a Canadian LP?
UK importers typically require four core documents: a current GMP certificate for the manufacturing site, batch-specific COAs from an ISO/IEC 17025-accredited lab, a CFIA phytosanitary certificate, and the Health Canada export permit for that shipment. Some importers conduct a paper-based supplier qualification audit before submitting the Home Office import licence application.
Does the Proceeds of Crime Act affect Canadian LP payments from UK partners?
The UK Proceeds of Crime Act 2002 creates technical money laundering considerations for UK entities transacting with overseas cannabis companies, even fully licenced ones. UK importers working with Canadian LPs operate through specialist banking arrangements. Canadian LPs entering the UK market should expect payment structure discussions to account for this legal context. Independent legal advice for both parties is strongly recommended.
